Journal of Blood & Lymph

Dr, Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Langen, Germany

Publications

• Mini Review   
  COVID-19 Convalescent Plasma: No Definite Answer Yet
  Author(s): Rainer Seitz*, Lutz Gürtler and Wolfgang Schramm
  
  The COVID-19 pandemic so far caused millions of deaths, and the therapeutic options for high-risk patients are far from being satisfactory. Active immunization by vaccines against SARS-CoV-2 spike protein provides good protection from a severe course of COVID-19. It has been explored in numerous clinical trials, whether also passive immunization by transfusion of convalescent plasma could positively influence the course of COVID-19. Large randomized clinical trials failed to demonstrate a benefit for patients with advanced disease. However, the antibody dose and timing of transfusion might have contributed to this negative result. Randomized clinical trials are necessary to make evidence-based progress in the development of therapeutic options, and this holds true also for “natural” concepts. However, even highquality trials are just a tool to test predef.. Read More»
  DOI: 10.37421/2165-7831.2021.11.265

  Abstract HTML PDF